Zhuo Wei

Zhuo Wei


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Journal of Immunology Research
Verified
Journal Article
Open access
MXMeiyi Xu
Meiyi Xu
CZCunling Zhang
Cunling Zhang
DWDan Wu
Dan Wu
LYLiying Yao
Liying Yao
MGMengyuan Geng
Mengyuan Geng
WLWen Li
Wen Li
Spontaneous preterm labor (SPTL) is a major cause of neonatal mortality and severe complications. T cells play a crucial role in mediating inflammation and immune tolerance at the maternal–fetal interface. T helper 17 cells (Th17, pro‐inflammatory) and regulatory T cells (Treg, anti‐inflammatory) are two subsets of CD4 + T cells with opposite functions, and their balance is important for maintaining immune homeostasis. Since infection and inflammation represent prominent factors responsible for the pathogenesis of SPTL, Th17/Treg imbalance at the maternal–fetal interface may trigger proinflammatory responses, potentially leading to SPTL. In this review, evidence from both clinical cases of SPTL and animal models indicates the presence of Th17/Treg imbalance in both peripheral blood and the maternal–fetal interface. Additionally, interleukin‐6 (IL‐6), interleukin‐1 β (IL‐1 β ), and interleukin‐8 (IL‐8) have been involved in the pathogenesis of inflammation‐induced SPTL, suggesting that Th17/Treg imbalance may have relevance to and be involved in the pathogenic process of SPTL. Moreover, the presence of Th17/Treg imbalance in risk factors for SPTL, such as autoimmune diseases and bacterial infections, further supports this connection indirectly. Although predictive models and interventional strategies related to SPTL have been explored, there is currently insufficient evidence to establish a direct causal relationship between Th17/Treg imbalance and the onset of SPTL.

17 April 2024 in Cell Biology and Toxicology
Verified
Journal Article
Open access
PDF file
CXChao Xue
Chao Xue
ZWZhuo Wei
Zhuo Wei
YZYe Zhang
Ye Zhang
YLYing Liu
Ying Liu
SZShuang Zhang
Shuang Zhang
YDYajun Duan
Yajun Duan
Cytosolic thiouridylase 2 (CTU2) is an enzyme modifying transfer RNAs post-transcriptionally, which has been implicated in breast cancer and melanoma development. And we found CTU2 participated in hepatocellular carcinoma (HCC) progression here. HepG2 cells as well as xenograft nude mice model were employed to investigate the role of CTU2 in HCC development in vitro and in vivo respectively. Further, we defined CTU2 as a Liver X receptor (LXR) targeted gene, with a typical LXR element in the CTU2 promoter. CTU2 expression was activated by LXR agonist and depressed by LXR knockout. Interestingly, we also found CTU2 took part in lipogenesis by directly enhancing the synthesis of lipogenic proteins, which provided a novel mechanism for LXR regulating lipid synthesis. Meanwhile, lipogenesis was active during cell proliferation, particularly in tumor cells. Reduction of CTU2 expression was related to reduced tumor burden and synergized anti-tumor effect of LXR ligands by inducing tumor cell apoptosis and inhibiting cell proliferation. Taken together, our study identified CTU2 as an LXR target gene. Inhibition of CTU2 expression could enhance the anti-tumor effect of LXR ligand in HCC, identifying CTU2 as a promising target for HCC treatment and providing a novel strategy for the application of LXR agonists in anti-tumor effect. Graphical Abstract 1.) CTU2 enhances proliferation of hepatoma carcinoma cells. 2.) CTU2 is the target gene of LXR, and LXR can transcriptionally activate CTU2 expression. 3.) CTU2 can promote protein synthesis of lipogenic genes. 4.) Inhibiting CTU2 expression can synergistically enhance the inhibitory effects of LXR ligands on HCC growth.

14 September 2022 in Maternal-Fetal Medicine
Verified
Journal Article
Open access
JCJiasong Cao
Jiasong Cao
YWYixin Wang
Yixin Wang
SWShuqi Wang
Shuqi Wang
YSYongmei Shen
Yongmei Shen
WLWen Li
Wen Li
YCYing Chang
Ying Chang
Steroid hormones, including progestagens, estrogens, androgens, corticosteroids, and their precursor cholesterol, perform essential functions in the successful establishment and maintenance of pregnancy and normal fetal development. As the core endocrine organ at the prenatal stage, the human placenta is involved in the biosynthesis, metabolism, and delivery of steroid hormones. Steroidogenic pathways are tightly regulated by placenta-intrinsic cytochrome P450 and hydroxysteroid dehydrogenase. However, the relationship between placental steroidogenic enzyme expression and adverse pregnancy outcomes is controversial. In this review, we summarize the possible upstream regulatory mechanisms of placental steroidogenic enzymes in physiologic and pathophysiologic states. We also describe the human placental barrier model and examine the potential of single-cell sequencing for evaluating the primary functions and cellular origin of steroidogenic enzymes. Finally, we examine the existing evidence for the association between placental steroidogenic enzyme dysregulation and adverse pregnancy outcomes.

20 October 2023 in Maternal-Fetal Medicine
Verified
Journal Article
Open access
YSYongmei Shen
Yongmei Shen
YLYaqi Li
Yaqi Li
JCJiasong Cao
Jiasong Cao
WLWen Li
Wen Li
QLQimei Lin
Qimei Lin
YCYing Chang
Ying Chang
In 2019, preterm births (PTB) accounted for approximately 0.66 million deaths globally. PTB is also associated with a significantly higher risk of mortality and long-term complications for newborns. Long-term studies associated several factors, including disruption of immune tolerance and inflammation, with PTB. However, the pathogenesis of PTB remains unclear. Gonadal steroid hormones are critical for pregnancy maintenance and regulation of immune and inflammatory responses. However, it is not clear how unbalanced gonadal steroid hormones, such as imbalanced estrogen/androgen or estrogen/progesterone contribute to PTB. In this review, we discuss how gonadal steroid hormones mediate dysfunction in immune tolerance and inflammatory responses, which are known to promote the occurrence of PTB, and provide insight into PTB prediction.

1 January 2026 in Journal of Diabetes Research
Verified
Journal Article
Open access
DWDan Wu
Dan Wu
MXMeiyi Xu
Meiyi Xu
CZCunling Zhang
Cunling Zhang
YBYuhong Bian
Yuhong Bian
LYLiying Yao
Liying Yao
WLWen Li
Wen Li
Background: Early prediction of gestational diabetes mellitus (GDM) enables timely interventions but remains challenging, particularly in women living without obesity who are often overlooked by standard screening methods. This exploratory analysis identifies early pregnancy biomarkers that show associations with GDM up to 8–12 weeks earlier than the established diagnostic timeframe. Methods: A retrospective nested case‐control study was conducted at Tianjin Central Hospital of Gynecology Obstetrics. After applying the predefined inclusion and exclusion criteria and removing cases with missing blood samples, a total of 136 women were included in the final analysis, comprising 56 women with GDM and 80 non‐GDM controls. These data were used to develop multiple machine learning models, including random forest, logistic regression, SVM, XGBoost, and KNN. The performance of these models was assessed by AUC, sensitivity, specificity, positive predictive value, and negative predictive value in an independent validation set. Results: The random forest classifier achieved the best performance with an AUC of 0.992 in the validation set, indicating excellent sensitivity and specificity. The model incorporated six measurable variables: age, BMI, and four cytokines (IL‐1 β , IL‐10, IL‐17A, and IL‐4) participating in immune regulation in pregnancy. Conclusions: GDM can be predicted with high accuracy early in pregnancy, even among women living without obesity. This study highlights the value of integrating immunological biomarkers with clinical characteristics and machine learning for proactive risk stratification. Although promising, our findings warrant validation in larger, multiethnic cohorts to ensure generalizability.

24 February 2023 in Research Square
Verified
Preprint
Open access
PDF file
YSYongmei Shen
Yongmei Shen
YLYaqi Li
Yaqi Li
XZXiaomin Zhao
Xiaomin Zhao
WLWen Li
Wen Li
LZLei Zhang
Lei Zhang
YCYing Chang
Ying Chang
Objective: To systematically analyze the genetic features of fetal renal abnormalities and the prenatal characteristics of 17q12 microdeletion syndrome. Methods: We retrospective analysis of fetal diagnosed with renal abnormalities from January 2016 to August 2022. Chromosome test, fetal renal abnormalities and pregnancy outcomes were performed in a descriptive analysis. Results: 141 patients (4.5%) showed abnormal renal development and 26 patients (26/141) with hyperechogenic kidneys (HCK), 14 (14/26) cases showed chromosomal abnormalities, 12 patients were 17q12 microdeletion syndrome. In addition, there were 14 17q12 microdeletion syndrome among the patients, and 12 fetal had hyperechogenic kidneys (HCK), 7 fetal were verified by couples, 5 fetal had new mutations, and 2 fetal inherited from parents. After excluding patients with HCK, the polycystic kidney has a higher rate of chromosomal abnormalities compared to polycystic renal dysplasia and renal dysplasia. The chromosomal of isolated horseshoe kidney, hydronephrosis, ectopic kidney and unilateral kidney often were normal, and the chromosomal abnormalities rate was increased when combined with other abnormalities. Conclusion: Fatal HCK was closely related to 17q12 microdeletion syndrome. The chromosome test result of patients with isolated polycystic kidney dysplasia, kidney dysplasia, horseshoe kidney, hydronephrosis, kidney deficiency, and ectopic kidney were mostly normal. Prenatal diagnosis was recommended, specifically in the fetus had non-isolated renal abnormalities. Most patients with normal chromosomes or uncertain clinical significance choose to produce, but adverse pregnancy outcomes were not excluded. This study will provide more data support for fetal renal abnormalities.